Shuang Huang

Shuang Huang, PhD

Professor

Department: MD-ANATOMY
Business Phone: (352) 273-6769
Business Email: shuanghuang@ufl.edu

Teaching Profile

Courses Taught
2016-2017,2019-2023
GMS6647 Transcriptional and Translational Control of Cell Growth and Proliferation
2020-2024
GMS6691 Special Topics in Cell Biology and Anatomy
2018,2020-2024
GMS6064 Tumor Biology
2018,2020-2024
GMS6421 Cell Biology
2018
GMS7979 Advanced Research
2018
GMS7980 Research for Doctoral Dissertation
2016
GMS6644 Apoptosis

Research Profile

Research in the Huang lab is concentrated on elucidating molecular mechanisms associated with breast and ovarian cancer metastasis. One of the current projects is to investigate how homeobox domain-containing proteins SHOX2 and HOXC8 regulate breast cancer metastasis with the focus on their role in epithelial-mesenchymal transition (EMT). Another project is based on our early discovery that the integrity of EPS8/ABI1/SOS1 tri-complex is critical for ovarian cancer metastasis. In this project, we are currently dissecting the players and pathways pertinent to the metastasis-promoting role of EPS8/ABI1/SOS1 tri-complex in ovarian cancer. In addition, the Huang lab is also working on identifying cancer driver genes/pathways in ovarian cancer, with the emphasis on developing targeted therapeutic strategies against ovary malignancies.

RESEARCH PROJECTS

Role of SHOX2 in breast tumor progression and metastasis R01, National Cancer Institute (CA187152) August 1, 2014 to July 31, 2019

Potential of Targeting PDE1C/2A for Suppressing Metastatic Ovarian Cancers Pilot Award, Department of Defense Ovarian Cancer Research Program July 1, 2013 to June 30, 2015

Open Researcher and Contributor ID (ORCID)

0000-0002-9674-2249

Publications

2023
ASC/inflammasome-independent pyroptosis in ovarian cancer cells through translational augmentation of caspase-1
iScience. 26(12) [DOI] 10.1016/j.isci.2023.108408. [PMID] 38058301.
2023
FAP is critical for ovarian cancer cell survival by sustaining NF-κB activation through recruitment of PRKDC in lipid rafts
Cancer Gene Therapy. 30(4):608-621 [DOI] 10.1038/s41417-022-00575-x. [PMID] 36494579.
2023
ROS-mediated SRMS activation confers platinum resistance in ovarian cancer
Oncogene. 42(20):1672-1684 [DOI] 10.1038/s41388-023-02679-6. [PMID] 37020040.
2022
Attenuated miR-203b-3p is critical for ovarian cancer progression and aptamer/miR-203b-3p chimera can be explored as a therapeutic
Advances in Cancer Biology – Metastasis. 4 [DOI] 10.1016/j.adcanc.2022.100031.
2021
Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB1
npj Breast Cancer. 7(1) [DOI] 10.1038/s41523-021-00300-1. [PMID] 34244488.
2020
Addiction to protein kinase Cɩ due to PRKCI gene amplification can be exploited for an aptamer-based targeted therapy in ovarian cancer.
Signal transduction and targeted therapy. 5(1) [DOI] 10.1038/s41392-020-0197-8. [PMID] 32820156.
2019
Isoliquiritigenin Inhibits Ovarian Cancer Metastasis by Reversing Epithelial-to-Mesenchymal Transition.
Molecules (Basel, Switzerland). 24(20) [DOI] 10.3390/molecules24203725. [PMID] 31623144.
2019
MicroRNA-744/transforming growth factor β1 relationship regulates liver cirrhosis.
Hepatology international. 13(6):814-825 [DOI] 10.1007/s12072-019-09993-w. [PMID] 31643031.
2019
Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.
Oncogene. 38(7):1106-1120 [DOI] 10.1038/s41388-018-0499-2. [PMID] 30209363.
2018
MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis.
Oncotarget. 9(1):1075-1090 [DOI] 10.18632/oncotarget.23262. [PMID] 29416678.
2018
Suppression of lung cancer progression by isoliquiritigenin through its metabolite 2, 4, 2′, 4′-Tetrahydroxychalcone.
Journal of experimental & clinical cancer research : CR. 37(1) [DOI] 10.1186/s13046-018-0902-4. [PMID] 30285892.
2018
The CPLANE protein Intu protects kidneys from ischemia-reperfusion injury by targeting STAT1 for degradation.
Nature communications. 9(1) [DOI] 10.1038/s41467-018-03628-8. [PMID] 29581513.
2017
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Journal of experimental & clinical cancer research : CR. 36(1) [DOI] 10.1186/s13046-016-0478-9. [PMID] 28069043.
2017
Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Cancer immunology research. 5(4):330-344 [DOI] 10.1158/2326-6066.CIR-16-0182. [PMID] 28264810.
2017
Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.
Theranostics. 7(5):1373-1388 [DOI] 10.7150/thno.17826. [PMID] 28435472.
2016
KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism.
Cell reports. 14(3):506-519 [DOI] 10.1016/j.celrep.2015.12.053. [PMID] 26774480.
2016
Persistent activation of autophagy in kidney tubular cells promotes renal interstitial fibrosis during unilateral ureteral obstruction.
Autophagy. 12(6):976-98 [DOI] 10.1080/15548627.2016.1166317. [PMID] 27123926.
2016
Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.
Cell reports. 17(2):609-623 [DOI] 10.1016/j.celrep.2016.09.021. [PMID] 27705805.

Grants

Sep 2021 ACTIVE
Novel protein kinase signaling associated with platinum resistance in ovarian cancer
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jul 2020 – Jun 2021
Early Detection of Breast Cancer in the Urine using CRISPR
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Sep 2018 ACTIVE
Impact of microRNA processing on EMT of ovarian cancer cells
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Sep 2016 – Aug 2020
Role of SHOX2 in breast tumor progression and metastasis
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jul 2016 – Jun 2018
Deterring breast cancer metastasis by restoring miRNA processing
Role: Principal Investigator
Funding: FL BREAST CANCER FOU

Education

Post Doctoral Fellowship
1996-1997 · American Cancer Society
PhD, Pharmacology
1994 · Baylor College of Medicine, Houston, Texas
BSc, Neurobiology
1983 · Fundan University, Shanghai, China

Contact Details

Phones:
Business:
(352) 273-6769
Emails:
Addresses:
Business Mailing:
PO Box 103633
GAINESVILLE FL 32610
Business Street:
CGRC 355
2033 MOWRY RD
Gainesville FL 32610